CoChat

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Background . Atherothrombotic disease, including coronary artery disease (CAD) and peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial infarction, stroke, limb ischemia, heart failure, and CV death. Aim . Evaluate the humanistic and economic burden of CAD and PAD and identify unmet needs through a comprehensive literature review. Methods . Relevant search terms were applied across online publication databases. Studies published between January 2010 and August 2017 meeting the inclusion/exclusion criteria were selected; guidelines were also included. Two rounds of screening were applied to select studies of relevance. Results . Worldwide data showed approximately 5–8% prevalence of CAD and 10–20% prevalence of PAD, dependent on the study design, average age, gender, and geographical location. Data from the REACH registry indicated that 18–35% of patients with CAD and 46–68% of patients with PAD had disease in one or more vascular beds. Use of medication to control modifiable CV risk factors was variable by country (lower in France than in Canada); statins and aspirin were the most widely used therapies in patients with chronic disease. Survival rates have improved with medical advancements, but there is an additional need to improve the humanistic burden of disease (i.e., associated disability and quality of life). The economic burden of atherothrombotic disease is high and expected to increase with increased survival and the aging population. Conclusion . CAD and PAD represent a substantial humanistic and economic burden worldwide, highlighting a need for new interventions to reduce the incidence of atherothrombotic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2019/8295054

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Baseline characteristics and medication use and clinical outcomes in patients with CAD and PAD from the REACH Registries of (a) Canada,a (b) France,b and (c) Germanyc [1, 2]. aPatients enrolled from January to October 2004; mean age 68.4 ± 9.9. bPercentage of patients experiencing at least one CV event (Figure (a): CAD n = 1356, PAD n = 146; Figure (b): CAD n = 2397, PAD n = 882; Figure (c): CAD n = 3328, PAD n = 1303). cPatients enrolled from December 2003 to June 2014; mean age 69.1–71.7 across risk groups. dPatients enrolled from December 2003 to June 2014; mean age 68.0–69.4 across risk groups. ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; CAD, coronary artery disease; CV, cardiovascular; PAD, peripheral artery disease.
Figure 1 Baseline characteristics and medication use and clinical outcomes in patients with CAD and PAD from the REACH Registries of (a) Canada,a (b) France,b and (c) Germanyc [1, 2]. aPatients enrolled from January to October 2004; mean age 68.4 ± 9.9. bPercentage of patients experiencing at least one CV event (Figure (a): CAD n = 1356, PAD n = 146; Figure (b): CAD n = 2397, PAD n = 882; Figure (c): CAD n = 3328, PAD n = 1303). cPatients enrolled from December 2003 to June 2014; mean age 69.1–71.7 across risk groups. dPatients enrolled from December 2003 to June 2014; mean age 68.0–69.4 across risk groups. ACE, angiotensin-converting enzyme; ASA, acetylsalicylic acid; CAD, coronary artery disease; CV, cardiovascular; PAD, peripheral artery disease.CC BY · PubMed Central
Figure 2 The persistent risk of MACE (a) up to 3 years following an index MI (adapted from Blin et al., 2016) [3] and (b) up to 4.5 years following an index MI stratified by age (<72 years old versus ≥72 years old) and risk category (low versus higha) (adapted from Jernberg et al., 2015) [4]. aHigh-risk patients were predefined as those with ≥1 of the following risk factors prior to index; MI: diabetes mellitus, at least one MI prior to index MI event, CABG (proxy for multi-vessel CAD), PAD, stroke, heart failure, or diagnosis of chronic renal dysfunction. CABG, coronary artery bypass graft; CAD, coronary artery disease; CV, cardiovascular; HR, high risk; LR, low risk; MACE, major adverse cardiovascular events; MI, myocardial infarction; PAD, peripheral artery disease.
Figure 2 The persistent risk of MACE (a) up to 3 years following an index MI (adapted from Blin et al., 2016) [3] and (b) up to 4.5 years following an index MI stratified by age (<72 years old versus ≥72 years old) and risk category (low versus higha) (adapted from Jernberg et al., 2015) [4]. aHigh-risk patients were predefined as those with ≥1 of the following risk factors prior to index; MI: diabetes mellitus, at least one MI prior to index MI event, CABG (proxy for multi-vessel CAD), PAD, stroke, heart failure, or diagnosis of chronic renal dysfunction. CABG, coronary artery bypass graft; CAD, coronary artery disease; CV, cardiovascular; HR, high risk; LR, low risk; MACE, major adverse cardiovascular events; MI, myocardial infarction; PAD, peripheral artery disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 8

  1. 2017, Heart and Metabolism, 9
  2. 2015, La Revue Du Praticien, 65, 317
  3. 2016, Vascular Medicine (United Kingdom), 21, 331
  4. 2018, International Angiology, 37, 327
  5. 2016, JACC: Journal of the American College of Cardiology, 69, e71
  6. 2016, Circulation: Cardiovascular Quality and Outcomes, 9, 731
  7. 2013, Health and Quality of Life Outcomes, 11
  8. 2010, Circulation: Cardiovascular Quality and Outcomes, 3, 642

Cited by

See all 482

Metadata

Authors
Bauersachs, R., Zeymer, U., Brière, J.-B., Marre, C., Bowrin, K., & Huelsebeck, M.
Affiliations
  • Johannes Gutenberg University Mainz (DE)
  • Klinikum Ludwigshafen (DE)
  • Bayer (Germany) (DE)
  • Creativ-Ceutical (France) (FR)
  • Bayer (United Kingdom) (GB)
Corresponding author
Bauersachs, Rupert
Venue
Cardiovascular Therapeutics
Publisher
Wiley
Published
2019-11-26
Volume
2019
Pages
1-9
ISSN
  • 1755-5914 (ISSN-L)
  • 1755-5922
OpenAlex
W2990657953
Cited by
449
References
52
Citations by year
2026: 39 · 2025: 80 · 2024: 118 · 2023: 102 · 2022: 64 · 2021: 38 · 2020: 8
FWCI
5.67
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Therapeutics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
Funders
  • Bayer AG
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
  • Health Sciences › Medicine › Epidemiology › Healthcare Systems and Public Health
Keywords
coronary artery disease, peripheral arterial disease, atherothrombosis, disease burden, economic burden, humanistic burden, prevalence, quality of life, disability, statins, aspirin, cardiovascular risk management, survival rate, population aging, unmet needs
MeSH terms
Aged, Coronary Artery Disease, Female, Health Services Needs and Demand, Humans, Male, Prognosis, Risk Factors, Global Health, Incidence, Prevalence, Health Care Costs, Cost of Illness, Peripheral Arterial Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.